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Recommended by Michael Peter Sarras
Bone Morphogenetic Protein (BMP-4) was shown to down-regulate melanogenesis, in part, by decreasing the level of tyrosinase
[Yaaretal.(2006)JBC:281].ResultspresentedhereshowthatBMP-4down-regulatedtheproteinlevelsofTRP-1,PKC-β,andMCI-
R. When paired cultures of human melanocytes were treated with vehicle or BMP-4 (25ng/ml), MAPK/ERK were phosphorylated
within one hour of BMP-4 treatment. Then the activated MAPK/ERK caused an acute phosphorylation of MITF, followed by
proteosome-mediated degradation of MITF, the key transcription factor for melanogenic proteins [Wu et al. (2000) Gene &
Development:14]. However, prolonged exposure of melanocytes to BMP-4 (up to 48 hours) caused a decrease in the level of
MITF-M transcript. In addition, BMP-4 decreased the intracellular level of cAMP, the key regulator of MITF expression. These
results demonstrate that BMP-4 activates MAPK/ERK signaling pathway to transiently activate MITF; however, chronic treatment
of BMP-4 to melanocytes causes a down-regulation of the expression of MITF, possibly in a cAMP-dependent pathway.
Copyright © 2009 Hee-Young Park et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Bone morphogenetic proteins (BMPs) are disulﬁde-linked
dimeric proteins, produced as large precursor proteins
(reviewed in [1]). BMPs can be further classiﬁed into several
subgroups by their amino acid similarities. BMP-2 and
BMP-4 have 83% amino acid sequence identity and are
the best-studied members in the BMP family (reviewed
in [1]). BMP-2 and -4 elicit their biological actions by
ﬁrst binding to their speciﬁc cell surface receptors, termed
type II receptor (BMPR-II) and type I receptor (BMPR
I) [2–6]. Two diﬀerent types of BMPR-I, termed BMP
type IA (BMPR-IA) and type IB (BMPR-IB), have been
identiﬁed [7–9]. Binding of BMP-2 and BMP-4 to BMPR-
II is facilitated by the type I receptors [4, 6]; and upon
binding with BMP-2 or -4, BMPR-II subsequently activates
type I receptors [10]. Activated BMPR-I phosphorylates
Smad-1, -5, or -8 [11], then recruits Smad-4, and the entire
complex translocates to the nucleus [12–14] and interacts
with speciﬁc DNA consensus sequences to either activate or
suppress transcription of target genes. Activated BMPR-I can
also phosphorylate (activate) extracellular-signal regulated
kinase (ERK) via mitogen activated protein kinase (MAPK)
and this pathway can also cross-talk with Smads-dependent
pathway [15, 16].
Recently, it was reported that BMP-4, a member of the
TGF-β superfamily (reviewed in [17]), negatively modulates
melanogenesis in part by reducing the level of tyrosinase
expression in cultured human melanocytes [18]. Treat-
ment of quail neural crest cultures with BMP-4 caused a
dramatic decrease in melanogenesis [19]. Moreover, in a
transgenic mouse model which overexpresses noggin, the
known physiological inhibitor of BMP-4 [20], the level
of microphthalmia-associated transcription factors (MITF),
and binding of α-melanocyte stimulating hormone (α-
MSH) to melanocortin receptor-1 (MC1-R) were increased,
resulting in darkening of the coat color [21].
The synthesis and dispersion of melanin within the
epidermis is largely responsible for skin color as well as
for protection from sun-induced injuries. Melanogenesis
is initiated when the amino acid tyrosine is oxidized to
dopa and dopa quinine by the enzyme tyrosinase, the key2 International Journal of Cell Biology
and rate-limiting enzyme in melanogenesis (reviewed in
[22]). Tyrosinase exists as an inactive form and is activated
when protein kinace c-β (PKC-β) phosphorylates the serine
residues in the cytoplasmic domain of this enzyme [23].
Activation of tyrosinase by PKC-β was shown to be required
for melanogenesis both in vivo [24] and in vitro [23, 25–27],
whileconverselyincreasedactivityand/orexpressionofPKC-
β leads to increased pigmentation both in vitro [28] and in
vivo [29].
Human melanogenesis is heavily inﬂuenced by both
paracrine and autocrine factors such as α-MSH [30],
endothelin-1 [31], interleukin-1 [32], and TNF-α [32].
Among these factors, α-MSH and endothelin-1 induce
pigmentation in part through increased expression and
activity of tyrosinase [30, 31, 33]. The expression of both
α-MSH and endothelin-1 was detected in epidermal ker-
atinocytes and induced when keratinocytes were exposed
to ultraviolet irradiation (UV) [31, 34]. Endothelin-1 was
shown to induce melanogenesis by activating multiple
signaling pathways, including the PKC-dependent pathway
[35]. On pigment cells, α-MSH ﬁrst binds to its cell
surface receptor MC1-R [36, 37], a heptahelical transmem-
brane protein coupled to the G-protein [38], and thereby
increases the intracellular level of cAMP [33]. One way
in which cAMP increases pigmentation is by increasing
the expression of MITF [39], shown to be a key tran-
scription factor for melanogenic protein, such as tyrosi-
nase and tyrosinase related protein-1 (TRP-1) and PKC-β
[40–42].
MITF is a basic-helix-loop-helix (bHLH) and leucine
zipper transcription factor that binds to conserved con-
sensus elements in gene promoters, speciﬁcally the M-
(AGTCATGTGCT) and E-(CATGTG) boxes [43], and reg-
ulates the transcription of tyrosinase, TRP-1, TRP-2 [41],
PKC-β [40], and MC1R [44]. MITF can bind as a homod-
imer or a heterodimer with another related family members
(reviewed in [45]). MITF comprises a family of at least
nine isoforms [46, 47], of which the MITF-M isoform
controls tyrosinase and PKC-β transcription in melanocytes
[40, 48, 49]. MITF activity and stability are regulated by
its phosphorylation state through MAPK/ERK-dependent
pathway [50, 51]. Upon phosphorylation, MITF binds to
either M-box or E-box consensus sequences to activate
transcription [51, 52], but phosphorylation then decreases
MITF stability and enhances its degradation in proteosomes
[50, 53]. Thus, prolonged activation of MAPK/ERK pathway
wouldresultindown-regulationofMITFproteinlevel.More
recently, MITF was shown to be a key transcription factor for
Rab27a [54], a protein important for melanosome transport,
and Pmel17 [48], a protein required for melanosome
matrix formation. Therefore, MITF plays a central role in
melanin synthesis, as well as melanosome biogenesis and
transport.
Whilefactorsthatincreasemelanogenesisarewellunder-
stood, physiological agents that suppress melanogenesis
are poorly understood. Recently, it has been shown that
interleukin-1α and -6, as well as TNF-α decrease melanogen-
esis in human melanocytes [32]. TGF-β was also shown to
decrease pigmentation [55].
In this paper, we further delineate the mechanism
by which the BMP-4-dependent signaling pathway down-
regulates melanogenesis. Speciﬁcally, the intracellular signal-
ing pathways that mediate the eﬀects of BMP-4 and its target
genes/proteins are explored.
2.MaterialsandMethods
2.1. Materials. Recombinant human BMP-4 was obtained
from R&D Systems, Inc., Minneapolis, MN. Dulbecco’s
modiﬁed essential medium (DMEM), L15, nonessential
amino acids, glutamine, Medium 199, and trypsin were pur-
chased from GIBCO/BRL, Gaithersburg, MD. Recombinant
basic ﬁbroblast growth factor was purchased from Amgen
Inc., Thousand Oaks, CA, bovine pituitary extract (BPE)
from Clonetics Corp., San Diego, CA, and hydrocortisone
from Calbiochem, San Diego, CA. Insulin, transferrin, and
dbcAMP were from Sigma Chemical Co., St. Louis, MO.
Nylon membranes and Tag-Ready-to-Go PCR Beads were
from Amersham Biosciences, Piscataway, NJ. Bovine calf
serum and fetal calf serum were from HyClone Laboratories,
Inc., Logan, UT. Polyvinyl diﬂuoride (PVDF) membranes
were from BioRad Laboratories, Carlsbad, CA. FuGene6 was
purchased from Roche Diagnostic Corp., Nutley, NJ. Lipo-
fectamine Plus reagent was from Invitrogen, Hercules, CA,
and promoterless renilla luciferase construct was purchased
from Promega, Madison, WI.
2.2. Antibodies. Monoclonal antibody speciﬁc for PKC-
β (dilution: 1:50) was purchased from BD Biosciences,
San Jose, CA. Polyclonal antibodies against phosphorylated
smad 1/5/8 (dilution: 1:10), TRP-1 (dilution: 1:1000), and
MCI-R (dilution: 1:100) were purchased from Santa Cruz
Biotechnology, Santa Cruz, CA. Monoclonal antibody for
tyrosinase (dilution: 1:1000) was purchased from Vector
Laboratories, Inc., Burlingame, CA. Monoclonal antibody
for MITF (dilution: 1:10) was a generous gift from Dr. David
Fisher at the Department of Dermatology, Massachusetts
General Hospital, Boston, MA.
2.3. Cells and Media. Neonatal foreskins were used to obtain
human melanocytes as previously described [23]. In brief,
the epidermis was separated from the dermis after overnight
incubation in 0.25% trypsin at 4◦C. Primary cultures were
then established in Medium 199 containing 1.8mM Ca+2
and supplemented with 10
−9 M triiodothyronine, 10μg/mL
insulin,1.4×10
−6 Mhydrocortisone,BPE(35ug/mL),80uM
dbcAMP, 10ng/mL basic ﬁbroblast growth factor, and 5–
10% fetal bovine serum. All post primary cultures were
maintainedinlowcalcium(0.03mM).Cellsatﬁrstorsecond
passage were used for all experiments. LH melanoma cells
were maintained in DMEM containing 10% of calf serum.
2.4. Immunoblot Analysis. Immunoblot analysis was per-
formed as previously described [23]. Cells were harvested
in RIPA buﬀer (0.25M Tris (pH 7.5), 0.5M NaCl, 2.5%
SDS, and 0.1% Triton-X-100) containing protease inhibitorsInternational Journal of Cell Biology 3
(100μM Okadaic acid, 100μM PMSF, 100μg/mL Apopro-
tinin, 2μg/mL Leupeptin, and 100μM Sodium Ortho-
Vanadate). Protein samples were subjected to 7.5% SDS-
PAGE and transferred to a PVDF membrane electrophoret-
ically. The membrane was preincubated in 100% Blotto
(5g nonfat dry milk in 100 mL phosphate buﬀered saline
(PBS)) for 1–3 hours at room temperature with shaking,
followed by an overnight incubation with antiserum (0.5–
1ug/mL in 10% Blotto) at 4◦C[ 18, 26, 50]. At the end of the
incubation, the membrane was washed extensively with PBS
containing 0.5% Tween-20, and processed using the ECL kit.
The membrane was then exposed to Kodak X-OMAT ﬁlm.
2.5. Vectors. PKC-β promoter-CAT reporter construct and
control expression vectors were obtained from Dr. Denise
Cooper at the University of South Florida [56].
2.6. Transient Transfection. In order to introduce PKC-β
promoter-CAT reporter construct into LH melanoma cells,
4ugofDNAwerepretreatedwithLipofectaminePlusreagent
and as an internal control for the transfection eﬃciency,
0.4ug of promoterless renilla Luciferase was cotransfected.
24 hours after transfections, cells were treated with vehicle or
BMP-4 (25ng/mL). Cells were then harvested from 48 to 72
hours after BMP-4 treatment. CAT and luciferase assays were
performed according to the manufacturer’s protocol.
2.7. Semi Quantitative RT-PCR. To determine the eﬀect of
BMP-4 on the level of PKC-β transcripts, semiquantita-
tive RT-PCR was ﬁrst performed. Speciﬁcally, cDNA was
made from total RNA isolated from melanocytes using
oligo pd (N)6 (Pharmacia Fine Chemicals, Piscataway, NJ).
Primers speciﬁc for PKC-β that recognize both βIa n d
βII were purchased from Oxford Biomedical Research,
Inc. For the internal control, primers against GAPDH
(forward:5 GTCATCATCTCCGCCCCTTC3  andbackward:
3 CCGCACTACCGGCACCCCGT5 ) were used. 0.1ug of
c D N Aw a sa m p l i ﬁ e dw i t h1 5 p m o lo fe a c hf o r w a r da n d
backward primers. Initially, 37 cycles of ampliﬁcation were
p e r f o r m e do nc D N Aa sw e l la so nR N Af r o me a c hs a m p l e
to assure no contamination of RNA samples with genomic
DNA. All PCR reactions were ampliﬁed for 29 cycles which
fell within the exponential phase of the ampliﬁcation for
optimal detection of PKC-β and BMP receptors and allow-
ing quantitative analysis of mRNA transcript modulation.
Denaturation was performed at 94◦C for 30 seconds, primer
annealing at 58◦Cf o r1m i n u t e ,a n dD N Ap o l y m e r i z a t i o n
at 72◦C for 1 minute in a thermal cycler (MJ Research
Inc., Waltham, MA). PCR products were separated over
a 1% agarose gel in 1X TAE and stained with ethidium
bromide. The levels of PCR products were subjected to the
densitometric analysis. PKC-β transcript levels were then
normalized against the level of GAPDH transcript.
2.8. Quantitative Real-Time PCR (qRT-PCR). The inﬂuence
of BMP-4 on the level of MITF-M in vehicle vs. BMP-
4 treated melanocytes was analyzed using MyiQTM
optical module Real-Time PCR system (Biorad) and
iQ SYBR Green Supermix containing the MITF-M
upstream primer: 5 CACGGGTCTCTGCTCTCC3  and
downstream primer: 5 GGTTGTTGTTGAAGGTGATGG3 .
A second set of MITF-M primers was designed
and used to conﬁrm the results: upstream primer:
5 ATAGAAAGTAGAGGGAGGGATAG5  and downstream
primer: 5 TTATTTGCTAAAGTGGTAGAAAGG3 . The PCR
reaction was performed in a 50uL volume containing 2–4ng
cDNA. The ﬁnal primer and probe concentrations were
optimized for each primer/probe combination. Two-step
PCR cycling was carried as follows: 95◦C5m i n u t e s× 1
cycle, 95◦C0 . 5m i n u t e ,5 5 ◦C0 . 5m i n u t e× 40 cycles. As
all internal control, GAPDH was ampliﬁed in parallel for
normalization.
2.9. Densitometric Analysis. Densitometric analysis was per-
formed by scanning the autoradiograms of western and
northern blots and PCR products into a computer (PC
DellTM). Intensity of each scanned band was determined
using BIO-RAD Gel Doc 1000/2000 imaging densitometer
after background subtraction.
3. Results
3.1. BMP-4 Decreased the Protein Levels of TRP-1, PKC-β,a n d
MC1-R. BMP-4 was shown to down-regulate melanogene-
sis, the key diﬀerentiated function of melanocytes, in part
by decreasing the expression of tyrosinase [18]. To examine
whether BMP-4 aﬀects the expression of other melanogenic
proteins, paired cultures of subconﬂuent primary human
melanocytes were treated with vehicle (4mM HCl/0.01%
BSA) or BMP-4 at 25ng/mL; the optimal concentration
to treat melanocytes as previously reported [18], for 24
and 48 hours and the protein levels of TRP-1, PKC-β,a n d
MC1-R were assessed, using speciﬁc antibodies against these
proteins. Results showed that BMP-4 decreased the protein
levelofPKC-βby49.9±29.7%(P<. 04)at24hoursand47.7
± 18.0% (P<. 04) at 48 hours (Figure 1(a)) ,am a g n i t u d eo f
reduction known to reduce tyrosinase phosphorylation and
activity in human melanocytes [23, 27] .T h ep r o t e i nl e v e lo f
TRP-1 was decreased by 45% ± 5.0% (P<. 05) and 36 ±
6.5.0% (P<. 045) at 24 and 48 hr time points, respectively
(Figure 1(b)) .T h ep r o t e i nl e v e lo fM C 1 - Rw a sd e c r e a s e db y
50% ± 2.0% (P<. 03) and 55% ± 2.5% (P<. 05) at 24
and 48 hours, respectively (Figure 1(c)). In summary, BMP-
4 reduced the protein levels of PKC-β, TRP-1, and MC1-R.
Earlier time points did not show signiﬁcant changes in the
levels of these proteins in response to BMP-4 treatment.
3.2. BMP-4 Activated Both Smads-1/5/8 and MAPK/ERK
Signaling Pathways. It is well documented that BMP-4
regulates transcription of target genes through Smads 1/5/8-
[11–14] and/or MAPK/ERK dependent pathways [15, 16].
To examine whether one or both of these pathways are
involved in mediating eﬀects of BMP-4 on the expression
of melanogenic proteins in human melanocytes, phospho-
rylation (activation) of Smads 1/5/8 by BMP-4 was ﬁrst
investigated. Paired cultures of melanocytes were treated4 International Journal of Cell Biology
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Figure 1: BMP-4 decreases the protein levels of PKC-β, TRP-1, and
MC1-R. Paired cultures of melanocytes were treated with either
vehicle or BMP-4 (25ng/mL). Cells were then harvested at 24 and
48 hours for immunoblot analysis using monoclonal antibodies
speciﬁc for PKC-β (a), TRP-1 (b), and MC1-R (c). The protein level
ofactinwasusedfortheloadingcontrol.ThelevelofPKC-β protein
wasdecreasedby49.9 ±29.7%(P<. 04)at24hoursandat48hours
by 47.7 ± 18% (P<. 04) [23, 27]. The levels of TRP-1 was decreased
by 45% ± 5.0% (P<. 05) and 36 ± 6.5.0% (P<. 045) at 24 and
48 hours time points, respectively (Figure 1(b)). The protein level
of MC1-R was decreased by 50% ± 2.0% (P<. 03) and 55% ±
2.5% (P<. 05) at 24 and 48 hours, respectively (Figure 1(c)). A
representative result from ﬁve separate experiments is shown.
with vehicle or BMP-4 (25ng/mL) for 2 and 4 hours as pre-
viouslydone[18].Thencellswereharvestedforimmunoblot
analysis using a polyclonal antibody that reacts against
phosphorylatedSmads-1/5/8.ResultsshowthatSmads-1/5/8
are phosphorylated by BMP-4 within 2 hours of treatment
(Figure 2(a)).
To investigate whether BMP-4 can also activate
MAPK/ERK-dependent pathway in human melanocytes,
paired cultures of melanocytes were treated with vehicle or
B M P - 4( 2 5n g / m L )f o r1 5a n d3 0m i n u t e s .T u m o rp r o m o t e r
phorbol dibutyrate (PDBu) was used as a positive control
as shown before [50]. As shown in Figure 2(b),E R K 1 / 2w a s
phosphorylated within 30 minutes of BMP-4 treatment. As
expected, PDBu phosphorylated ERK1/2 within 15 minutes
of treatment. These results suggest that both Smads-1/5/8
and MAPK/ERK-pathways are activated by BMP-4 and
2hr
V BMP-4 V BMP-4
4hr
Smad-1/5/8 P
Actin
(a)
V
PDBu
15min 15min 30min 30min
BMP-4
ERK 1/2
Total-ERK 1/2
P
Actin
(b)
Figure 2: BMP-4 activates Smad 1/5/8 and MAPK/ERK in cultured
melanocytes. (a) Paired cultures of melanocytes were treated with
vehicle or BMP-4 (25ng/mL) for 2 and 4 hours. At each time point,
cells were harvested and immunoblot analysis using polyclonal
antibody against phosphorylated Smad 1/5/8 was performed. As
the loading control, the membrane was immunoblotted for actin.
Onerepresentativeresultfromthreeseparateexperimentsisshown.
(b) Paired cultures of melanocytes were treated with vehicle or
BMP-4 (25ng/mL) for 15 and 30 minutes. At each time point,
cells were harvested and immunoblot analysis using polyclonal
antibody against phosphorylated and nonphosphorylated ERK was
performed; PDBu at 1 × 10
−6 M was used as a control. As the
loading control, the membrane was immunoblotted for actin. One
representative result from three separate experiments is shown.
may be involved in mediating BMP-4 responses in cultured
human melanocytes.
3.3. Level of Phosphorylated MITF is Transiently Increased by
BMP-4. It is well known that activated MAPK/ERK pathway
can phosphorylate MITF, which results in a transient activa-
tion and then degradation of MITF [50, 51]. MITF is the key
transcription factor that regulates the expression of TRP-1,
PKC-β, and MC1-R. Therefore, it is possible that the eﬀect
of BMP-4 on the expression of these melanogenic proteins is
mediated in part or totally through MITF. To test whether
BMP-4 treatment causes phosphorylation of MITF, paired
culturesofmelanocytesweretreatedwithBMP-4(25ng/mL)
for 0, 0.5, 1, 2, and 5 hours. Results show a high basal level
of phosphorylated MITF (0hr). Then the level of phospho-
rylated MITF increased by a 2–4 fold (P<. 03) at 1 hour,
and there was a subsequent reduction at 5 hours time point
(Figure 3(a)). To conﬁrm that phosphorylation of MITF
by BMP-4 treatment is mediated through MAPK/ERK-
dependent pathway, paired cultures of melanocytes were
treated with MAKP inhibitor PD98056 (10uM) or vehicleInternational Journal of Cell Biology 5
00 . 51
BMP-4 (hrs)
25
MITF-
MITF
Actin
P
(a)
15 min 30 min 15 min 30 min
V BMP-4 VV PD98509 V PD98509 BMP-4 BMP-4 BMP-4
PD98509+ PD98509+
MITF-
MITF
Actin
P
(b)
BMP-4/CHX (hrs) BMP-4/CHX/MG-132 (hrs)
00 . 5 2 0 .51 2 5 5 10
MITF-
MITF
Actin
P
(c)
Figure 3:EﬀectsofBMP-4onthelevelofphosphorylatedlevelofMITF.(a)PairedculturesofmelanocytesweretreatedwithBMP-4(25ng/mL)
for 0, 0.5, 1, 2, and 5 hours. At each time point, cells were harvested and immunoblot analysis using monoclonal antibody against MITF
was performed (provided by Dr. David Fisher from the Dana Farber Cancer Institute). This antibody has been shown to recognize both
phosphorylated and nonphosphorylated MITF. As the loading control, the membrane was immunoblotted for actin. One representative
result from three separate experiments is shown. (b) Paired cultures of melanocytes were treated with BMP-4 (25ng/mL) for 15 and 30
minutes in presence or absence of MEK inhibitor PD98509 at 10 μm. At each time point, cells were harvested and the level of MITF protein
was determined. One representative result from three separate experiments is shown. (c) Paired cultures of melanocytes were treated with
BMP-4 (25ng/mL) and cycloheximide (15ug/mL) for 0, 0.5, 1, 2, and 5 hours in presence or absence of proteosome inhibitor MG-132 at 10
μm. At each time point, cells were harvested and the level of MITF protein was determined using immunoblot analysis. One representative
result from three separate experiments is shown.
(DMSO). PD98056 completely blocked the BMP-4 induced
MITF phosphorylation (Figure 3(b)), conﬁrming that BMP-
4 phosphorylates MITF through MAPK/ERK-dependent
pathway.
Since it is well known that phosphorylation of MITF by
MAPK/ERK-dependent pathway results in the proteosome-
mediated degradation of MITF [50, 51], the decreased level
of MITF by BMP-4 treatment at 4 to 5 hours is likely due
to degradation of MITF. To further conﬁrm this possibility,
paired cultures of melanocytes were treated with BMP-
4 (25ng/mL) for 0, 1, 2, 3, and 5 hours in presence or
absence of proteosome inhibitor MG-132 (10uM). Protein
synthesis inhibitor cyclohexamide (15ug/mL) was added
to all treatment groups. Results show that BMP-4 ﬁrst
increased the level of phosphorylated MITF (0.5 to 1 hour)
as expected and then the level of MITF began to decline at
2 hours and was signiﬁcantly reduced at 5 hours. Presence
of the proteosome inhibitor MG-132 completely blocked
the degradation of MITF (Figure 3(c)). These results clearly
demonstrate that BMP-4 transiently phosphorylated MITF,
thus potentially promote acute melanogenesis, followed by
down-regulation.
3.4. Chronic Treatment of BMP-4 Decreased Total MITF. If
BMP-4causesatransientphosphorylationofMITF,followed
by proteosome-mediated degradation, then a long term
treatment of BMP would ultimately result in a decreased
level of total MITF. To test this possibility, paired cultures of6 International Journal of Cell Biology
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Figure 4: BMP-4 reduces the level of total MITF protein.( a )
Paired cultures of melanocytes were treated with vehicle or BMP-
4 for 24 and 48 hours. At each time point, cells were harvested
and immunoblot analysis using monoclonal antibody against
MITF was performed. As the loading control, the membrane was
immunoblotted for actin. One representative result from three
separate experiments is shown. (b) In parallel, total RNA was
isolated and quantitative Real-Time PCR was performed using
speciﬁc primers against MITF-M as described under the Materials
and Methods. Paired student t-test was performed for the statistical
analysis.
melanocytes were treated with BMP-4 (25ng/mL) or vehicle
alone for 24 or 48 hours. Immunoblot analysis using a
speciﬁcmonoclonalantibody againstMITFthatdetectsboth
phosphorylated and nonphosphorylated MITF revealed that
BMP-4 dramatically decreased the levels of both forms of
MITF at both 24 and 48 hours time points (Figure 4(a)).
To further examine whether the decreased level of
MITF by chronic treatment of melanocytes with BMP-4
is entirely due to the proteosome-mediated degradation
of MITF or BMP-4 could also reduce the level of MITF
transcripts, paired cultures of melanocytes were treated with
vehicle or BMP-4 (25ng/mL) for 4, 24, and 48 hours and
total RNA was isolated. RNA was reverse transcribed into
cDNA and the level of MITF-M transcripts between vehicle
treated and BMP-4 treated samples was determined using
quantitative Real-Time PCR. The level of GAPDH transcript
was used as the internal control. The MITF-M transcript
level remained unchanged at 4 and 24 hours after the BMP-4
treatment (Figure 4(b)). However, after 48 hours of BMP-4
treatment, the level of MITF-M transcript was signiﬁcantly
(P = .039) decreased (Figure 4(b)). These results suggest
that the decreased protein level of MITF by BMP-4 is
initially due to the proteosome-mediated degradation. BMP-
4 then subsequently decreased the expression of MITF at the
transcriptional level.
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Figure 5: BMP-4 decreases the intracellular level of cAMP.P a i r e d
cultures of melanocytes were treated with BMP-4 for 0, 1, 18, 24,
and 48 hours. At each time point, cells were harvested and the level
of intracullelar cAMP level was determined. One representative
result from three separate experiments is shown.
3.5. BMP-4 Reduces the Intracellular Level of cAMP in
Melanocytes. Results thus far suggest that BMP-4 transiently
activates MITF through MAPK/ERK-dependent pathway.
Our results also suggest that BMP-4 transcriptionally regu-
lates the expression of MITF. Recent reports have suggested
thatcAMP-dependentpathwaymay mediate BMP-4induced
changes [57]. Because cAMP has been implicated to be
the key molecule inducing pigmentation [39, 41], in part
through inducing the expression of MITF-M [40], possible
eﬀects of BMP-4 on the level of intracellular cAMP in
cultured human melanocytes were explored. Paired cultures
of subconﬂuent melanocytes were treated with BMP-4
(25ng/mL). Then cells were harvested at each time point
and the level of cAMP was measured using enzyme-linked
immunoblot assay (ELISA). Within 18 hours of BMP-4
treatment, cAMP level began to decrease and by 48 hours,
BMP-4 signiﬁcantly reduced the intracellular level of cAMP
(Figure 5). This result suggests that part of BMP-4 eﬀects on
the expression of MITF may be mediated through cAMP-
dependent pathway.
3.6. Eﬀect of BMP-4 on the Promoter Activity of PKC-β. It is
not clear to what extent Smads-1/5/8 pathway is involved in
mediating the eﬀects of BMP-4 on the expression of TRP-1,
PKC-β, MC1-R, and MITF. Published nucleotide sequences
of the promoter regions of tyrosinase, and PKC-β revealed
that they both contain consensus sequences for Smad-1 and
Smad-5 [58, 59], suggesting that BMP-4 could regulate the
expression of these two key melanogenic proteins through
Smad-dependent pathway.
To explore the possibility that BMP-4 may regulate PKC-
β expression, in part, by suppressing the promoter activity
of the PKC-β gene, presumably through Smad-dependent
pathway, the level of PKC-β transcripts was ﬁrst examined
usingsemiquantitativeRTPCR.AsshowninFigure 6(a),twoInternational Journal of Cell Biology 7
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Figure 6: BMP-4 decreases the levels of PKC-β in mRNA in LH
melanoma cells. Quantitative Real-Time PCR was performed using
the same cDNA used in semi-quantitative RT-PCR (a). The level
of PKC-β transcripts were normalized using the level of GAPDH
transcripts. Results were then expressed as the percent of the
vehicle-treated samples (b). In three independent experiments,
BMP-4 signiﬁcantly decreased the level of PKC-β transcripts (P<
.03).
transcripts of PKC-β were identiﬁed and the levels of both
transcripts were signiﬁcantly decreased by BMP-4 (Figure 6).
To demonstrate whether BMP-4 aﬀects the promoter
activity of PKC-β,P K C - β promoter-CAT reporter construct
[56] was transfected into LH human melanoma cells that
were originally cultured from a metastatic melanoma [60].
Unlikemanyothermelanomalines,inwhichtheendogenous
expression of PKC-β is lost [61, 62], LH human melanoma
cells retain the expression of PKC-β,a n de x p r e s sb o t h
BMPR-IA/IB and BMPR-II (data not shown). Moreover, the
expression of PKC-β in LH melanoma cells respond to BMP-
4 similar to those found in cultured melanocytes where
both the protein and the mRNA of PKC-β were reduced by
treating the cells with BMP-4 (25ng/mL) for 24 hours (data
not shown). Then, to examine whether BMP-4 suppresses
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Figure 7: Eﬀects of BMP-4 on the promoter activity of PKC-β.I n
order to determine whether BMP-4 aﬀects promoter activity of
PKC-β, paired cultures of LH melanoma cells were transfected with
PKC-β promoter CAT reporter construct along with promoter-less
renilla luciferase to assess the transfection eﬃciency, and treated
with BMP-4 for 48 hours. Cells were harvested and CAT and
Luciferase activities were performed. A total of eight separate
transfections were performed, data were pulled and expressed as a
percent of vehicle-treated samples. BMP-4 decreased the promoter
activity of PKC-β by 25 ± 5% (P<. 01).
the promoter activity of PKC-β,aP K C - β promoter-CAT
reporter construct was transfected into paired cultures of LH
melanoma cells. A promoterless renilla-luciferase reporter
construct was cotransfected into each plate to normalize
the transfection eﬃciency among plates, and results were
expressed as CAT activity per luciferase activity. Plates
were treated with BMP-4 (25ng/mL) or vehicle alone 24
hours after transfection, and cells were harvested 48 hours
after BMP-4 treatment. In eight separate experiments, the
promoter activity of PKC-β was reduced by ∼25 ± 5% in
BMP-4-treated cells when compared to vehicle-treated cells
(Figure 7). A paired Student t-test showed that suppression
of the promoter activity of PKC-β by BMP-4 was statistically
signiﬁcant (P<. 01). Although the eﬀect of BMP-4 on
the promoter activity of PKC-β was statistically signiﬁcant,
the total level of reduction was modest and less than the
reduction level seen in both PKC-β mRNA and protein
levels. These results suggest that BMP-4 utilizes only partially
Smads-dependent pathway to regulate the expression of
PKC-β.
4. Discussion
Bone morphogenetic proteins (BMPs) were shown to be
important for the development of melanoblasts during
embryogenesis (reviewed in [19]). In recent years, it has8 International Journal of Cell Biology
been shown that BMPs, BMP 2/4 in particular, may play key
roles in the biological function of diﬀerentiated epidermal
melanocytes as a paracrine and/or autocrine factor by
inﬂuencing the activities of melanocytes. Both epidermal
keratinocytes and melanocytes express BMP-4 and its recep-
tors; BMPR-IA, BMPR-IB, and BMPR-II, and both BMP-4
and all three BMP-4 receptors are down-regulated in these
cells when exposed to UV [18]. Moreover, BMP-4 and its
signaling pathway have recently been suggested to be a novel
modulator of human pigmentation [18].
BMP-4 is able to exert its biological action through
Smads- and/or MAPK/ERK signaling pathways [15, 16]. Our
results showed that BMP-4 treatment caused activation of
both signaling pathways. However, results strongly suggest
that BMP-4 preferentially utilizes MAPK/ERK-pathway to
regulate synthesis of melanin or melanogenesis once it
binds to its cell surface receptors. Experiments presented
in this paper demonstrate that one of the major target
proteins of BMP-4 activated MAPK/ERK pathway in human
melanocytes is MITF. Modulation of activity and/or expres-
sion of MITF could have a signiﬁcant impact on the biology
of melanocytes because MITF is the central transcription
factor for many of the melanogenic proteins, including
tyrosinase [41], TRP-1, [41]P K C - β [40–42], and MC1R
[44], as well as antiapoptotic protein bcl2 [63]. When BMP-
4 is added to the melanocyte cultures, MITF is transiently
phosphorylated by BMP-4 via MAPK/ERK-dependent sig-
naling pathway and this phosphorylation initially activates
thetranscriptionalactivityofMITF,aspreviouslyshown[50,
51]. Therefore, BMP-4 can acutely promote melanogenesis.
However, the phosphorylated MITF results in proteosome-
mediated degradation, as previously reported [53]. The
eventualdecreasedlevelofMITFbyBMP-4wouldthencause
an overall decrease in the levels of melanogenic proteins and
thus, cause down-regulation of melanogenesis.
Cell surface receptor c-kit, known to be activated after
the interaction with its ligand Stem cell factor (CSF), was
one of the ﬁrst cell surface receptors on melanocytes that
was shown to activate MAPK/ERK pathway that causes the
transient phosphorylation of MITF and thus, activation of
this transcription factor [51]. It was recently shown that c-
kit has a soluble form that is released from melanocytes and
sequesters CSF and therefore, inhibits melanogenesis [64].
It would be interesting to determined whether BMP-4 and
soluble c-kit could work synergistically to down-regulate the
level of MITF.
Our results further suggest that eﬀects of BMP-4 on
the expression of TRP-1, PKC-β, and MC1-R are mainly
mediated indirectly through decreasing the level of MITF.
Decreased level of MITF would then lead to a decreased level
of transcriptional activities of these genes. In fact, it caused a
reduction in the level of the transcripts of PKC-β.H o w e v e r ,
part of reduction in PKC-β transcripts by BMP-4 is through
Smad-dependent pathway, as explained later. Nonetheless,
MAPK/ERK-dependant pathway appears to play a larger
contribution to the reduced level of PKC-β through MITF.
Our results further suggest that BMP-4 down-regulates
the protein level of MITF ﬁrst by proteosome-mediated
degradation. It is then followed by a decrease in the level
of MITF-M transcripts, suggesting that BMP-4 can tran-
scriptionally down-regulate the expression of MITF-M. This
decrease in the level of MITF-M may be mediated by cAMP-
dependent pathway. Results showed that BMP-4 decreased
the intracellular level of cAMP. It has been reported that
BMP-4 can regulate the intracellular level of cAMP [19, 65,
66]. In melanocytes it is not clear whether BMP-4 down-
regulates the intracellular level of cAMP through down-
regulating the expression of MC1-R, or by other mechanism.
It is unlikely that Smads-dependent pathway is involved
in down-regulation of MITF-M transcripts because the
promoter region of MITF gene does not contain DNA
consensus sequences for Smads binding sites [46].
MITF was also shown to positively regulate the expres-
sion of the antiapoptotic protein bcl2 [63]. Therefore,
decreased level of MITF by BMP-4 could eventually aﬀect
the survival of melanocytes. Yaar et al. have reported that
short-term exposure of BMP-4 to melanocytes did not
change the proliferation rate and it did not cause apoptosis
of melanocytes [18]. However, BMP-4 could potentially
increase the susceptibility of melanocytes to damages such as
UV and other chemical agents that could reduce survival of
melanocytes. Therefore, role of BMP-4 on melanocyte may
have implications beyond its role in melanogenesis.
Smads 1, 5, and/or 8 were phosphorylated by BMP-4
within 2 hours of treatment in cultured human melanocytes.
Moreover, Yaar et al. have shown that activated (phospho-
rylated) Smad 1, 5, and/or 8 translocates to nucleus [18].
Among the melanogenic proteins examined, only the pro-
moterregionsofPKC-β revealtwelveSmad-1andoneSmad-
5 consensus sequences [58], suggesting that BMP-4 could
directly regulate the transcriptional activity of the PKC-
β gene. Transfection of a PKC-β promoter–CAT reporter
construct into LH cells showed modest but signiﬁcant
suppressions of PKC-β promoter–CAT reporter activity. The
l e v e lo fd e c r e a s ei nP K C - β transcript by BMP-4 was greater
than the suppression of the PKC-β promoter activity. These
results suggest that the eﬀect of BMP-4 on PKC-β expression
may involve direct transcriptional regulation. However,
clear demonstration of direct interaction between PKC-β
promoter and Smads 1, 5, and/or 8 would require additional
experiments involving gel-shifts and/or CHIP assays.
In murine melanoma cells, TGF-β decreases pigmenta-
tion by decreasing the stability of tyrosinase mRNA and
protein [67], as well as decreasing the level and the activity
of MITF [55]. TGF-β was shown to decrease only the level
of phosphrylated MITF [55]. However, results presented
in this paper show that the levels of both phosphorylated
and nonphosphorylated MITF were decreased by BMP-4 in
cultured human melanocytes. Even though BMP-4 belongs
to the superfamily of TGF-β, their detailed mechanisms of
action may diﬀer with regard to melanogenesis.
The ﬁndings of the present in vitro studies are likely of
great in vivo relevance, as transgenic mice in which BMP-
4 action is antagonized by overexpression of its physiologic
inhibitor noggin in hair follicles have a markedly darker coat
color [21].
Our results suggest that the BMP-4-dependent pathway
is a key physiologic negative modulator of melanogenesis,International Journal of Cell Biology 9
suppressing the expression of melanogenic proteins and
signaling molecules. BMP-4 may thus provide a novel target
for modulation of melanogenesis.
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